When your pricing doesn’t add up…it’s time to consider outcome- and value-based pricing models
Whatever pricing and contract alternative model you’re exploring, such reimbursement scenarios would benefit the entire healthcare system and more clearly align all the players with patient outcomes. As the manufacturer, you would require a greater stake in the outcomes to justify the high costs for your products. Providers would benefit with higher patient success rates, and payers would get patients back to a healthy state, while reducing costly hospital stays or readmissions.
3 emerging value- and outcome-based drug pricing models tied to contract agreements are geared toward improving access and affordability, while benefiting you as the manufacturer.
Learn more about these emerging models
HOW VISTEX SOLVES
1 & 2. Cost sharing
and risk sharing
3. Outcome-based contracts with
flexibility in payment scheme